Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.

Journal

Targeted oncology

ISSN: 1776-260X

Titre abrégé: Target Oncol

Pays: France

ID NLM: 101270595

Informations de publication

Date de publication:
30 Apr 2024

Historique:

accepted: 03 04 2024

medline: 1 5 2024

pubmed: 1 5 2024

entrez: 30 4 2024

Statut: aheadofprint

Résumé

In the context of patients with hepatocellular carcinoma (HCC) treated with systemic therapy, the correlation between the appearance of adverse events (AEs) and reported efficacy outcomes is well-known and widely investigated. From other pathological settings, we are aware of the prognostic and predictive value of the occurrence of immune-related AEs in patients treated with immune-checkpoint inhibitors. This retrospective multicenter real-world study aims to investigate the potential prognostic value of AEs in patients with HCC treated with atezolizumab plus bevacizumab in the first-line setting. The study population consisted of 823 patients from five countries (Italy, Germany, Portugal, Japan, and the Republic of Korea). Of the patients, 73.3% presented at least one AE during the study period. The most common AEs were proteinuria (29.6%), arterial hypertension (27.2%), and fatigue (26.0%). In all, 17.3% of the AEs were grade (G) 3. One death due to bleeding was reported. The multivariate analysis confirmed the appearance of decreased appetite G < 2 [versus G ≥ 2; hazard ratio (HR) 0.60; 95% confidence interval (CI) 0.13-0.90; p < 0.01] and immunotoxicity G < 2 (versus G ≥ 2; HR: 0.70; 95% CI 0.24-0.99; p = 0.04) as independent prognostic factors for overall survival, and the appearance of decreased appetite G < 2 (versus G ≥ 2; HR: 0.73; 95% CI 0.43-0.95; p = 0.01), diarrhea (yes versus no; HR: 0.57, 95% CI 0.38-0.85; p = 0.01), fatigue (yes versus no; HR: 0.82, 95% CI 0.65-0.95; p < 0.01), arterial hypertension G < 2 (versus G ≥ 2; HR: 0.68, 95% CI 0.52-0.87; p < 0.01), and proteinuria (yes versus no; HR: 0.79, 95% CI 0.64-0.98; p = 0.03) as independent prognostic factors for progression-free survival. As demonstrated for other therapies, there is also a correlation between the occurrence of AEs and outcomes for patients with HCC for the combination of atezolizumab plus bevacizumab.

Sections du résumé

BACKGROUND BACKGROUND

OBJECTIVE OBJECTIVE

This retrospective multicenter real-world study aims to investigate the potential prognostic value of AEs in patients with HCC treated with atezolizumab plus bevacizumab in the first-line setting.

PATIENTS AND METHODS METHODS

The study population consisted of 823 patients from five countries (Italy, Germany, Portugal, Japan, and the Republic of Korea).

RESULTS RESULTS

Of the patients, 73.3% presented at least one AE during the study period. The most common AEs were proteinuria (29.6%), arterial hypertension (27.2%), and fatigue (26.0%). In all, 17.3% of the AEs were grade (G) 3. One death due to bleeding was reported. The multivariate analysis confirmed the appearance of decreased appetite G < 2 [versus G ≥ 2; hazard ratio (HR) 0.60; 95% confidence interval (CI) 0.13-0.90; p < 0.01] and immunotoxicity G < 2 (versus G ≥ 2; HR: 0.70; 95% CI 0.24-0.99; p = 0.04) as independent prognostic factors for overall survival, and the appearance of decreased appetite G < 2 (versus G ≥ 2; HR: 0.73; 95% CI 0.43-0.95; p = 0.01), diarrhea (yes versus no; HR: 0.57, 95% CI 0.38-0.85; p = 0.01), fatigue (yes versus no; HR: 0.82, 95% CI 0.65-0.95; p < 0.01), arterial hypertension G < 2 (versus G ≥ 2; HR: 0.68, 95% CI 0.52-0.87; p < 0.01), and proteinuria (yes versus no; HR: 0.79, 95% CI 0.64-0.98; p = 0.03) as independent prognostic factors for progression-free survival.

CONCLUSIONS CONCLUSIONS

As demonstrated for other therapies, there is also a correlation between the occurrence of AEs and outcomes for patients with HCC for the combination of atezolizumab plus bevacizumab.

Identifiants

DOI: 10.1007/s11523-024-01061-0 PMID: 38689194

pubmed: 38689194

doi: 10.1007/s11523-024-01061-0

pii: 10.1007/s11523-024-01061-0

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.

pubmed: 33479224 doi: 10.1038/s41572-020-00240-3

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

pubmed: 18650514 doi: 10.1056/NEJMoa0708857

Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.

pubmed: 19095497 doi: 10.1016/S1470-2045(08)70285-7

Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.

pubmed: 29433850 doi: 10.1016/S0140-6736(18)30207-1

Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–73.

pubmed: 34902530 doi: 10.1016/j.jhep.2021.11.030

Ghassan KAA, George L, Cheng AL, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM. 2022;1(8): EVIDoa2100070.

Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93.

pubmed: 34801630 doi: 10.1016/j.jhep.2021.11.018

Sung MW, Finn RS, Qin S, et al. Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT). J Clin Oncol. 2019;37(4):317.

doi: 10.1200/JCO.2019.37.4_suppl.317

Ohki T, Sato K, Kondo M, et al. Impact of adverse events on the progression-free survival of patients with advanced hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study. Drugs Real World Outcomes. 2020;7:141–9.

pubmed: 32048238 pmcid: 7221074 doi: 10.1007/s40801-020-00179-7

Shimose S, Iwamoto H, Niizeki T, et al. Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study. Cancers (Basel). 2020;12(7):1867.

pubmed: 32664489 pmcid: 7408786 doi: 10.3390/cancers12071867

Rapposelli IG, Tada T, Shimose S, et al. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver Int. 2021;41:2997–3008.

pubmed: 34250737 doi: 10.1111/liv.15014

Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52:512–9.

pubmed: 27704266 doi: 10.1007/s00535-016-1263-4

Koizumi Y, Hirooka M, Hiraoka A, et al. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma. Endocr J. 2019;66(9):787–92.

pubmed: 31142692 doi: 10.1507/endocrj.EJ19-0140

Shomura M, Okabe H, Sato E, et al. Hypothyroidism is a predictive factor for better clinical outcomes in patients with advanced hepatocellular carcinoma undergoing lenvatinib therapy. Cancers (Basel). 2020;12(11):3078.

pubmed: 33105621 pmcid: 7690372 doi: 10.3390/cancers12113078

Persano M, Casadei-Gardini A, Burgio V, Scartozzi M, Cascinu S, Rimini M. Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors? Expert Rev Anticancer Ther. 2023;23(1):19–27.

pubmed: 36472371 doi: 10.1080/14737140.2023.2156340

Marisi G, Cucchetti A, Ulivi P, et al. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? World J Gastroenterol. 2018;24(36):4152–63.

pubmed: 30271080 pmcid: 6158485 doi: 10.3748/wjg.v24.i36.4152

Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15:85–92.

pubmed: 20051477 pmcid: 3227883 doi: 10.1634/theoncologist.2009-0143

Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61:318–24.

pubmed: 24703956 doi: 10.1016/j.jhep.2014.03.030

Wang P, Tan G, Zhu M, Li W, Zhai B, Sun X. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12:1–8.

pubmed: 28847184 doi: 10.1080/17474124.2017.1373018

Casadei Gardini A, Scarpi E, Marisi G, et al. Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. Oncotarget. 2016;7:15243–51.

pubmed: 26893366 doi: 10.18632/oncotarget.7444

Zhong BY, Ni CF, Chen L, Zhu HD, Teng GJ. Early sorafenib-related biomarkers for combination treatment with transarterial chemoembolization and sorafenib in patients with hepatocellular carcinoma. Radiology. 2017;284:583–92.

pubmed: 28263701 doi: 10.1148/radiol.2017161975

Howell J, Pinato DJ, Ramaswami R, et al. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-center, prospective study. Aliment Pharmacol Ther. 2017;45:1146–55.

pubmed: 28252185 doi: 10.1111/apt.13977

Shin SY, Lee YJ. Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib. Int J Clin Pharmacol Ther. 2013;51:837–46.

pubmed: 24075093 doi: 10.5414/CP201907

Otsuka T, Eguchi Y, Kawazoe S, et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2012;42:879–86.

pubmed: 22469363 doi: 10.1111/j.1872-034X.2012.00991.x

Bettinger D, Schultheiss M, Knüppel E, Thimme R, Blum HE, Spangenberg HC. Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 2012;56:789–90.

pubmed: 22307848 doi: 10.1002/hep.25637

Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology. 2013;84:6–13.

pubmed: 23075905 doi: 10.1159/000342425

Di Costanzo GG, De Stefano G, Tortora R, et al. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncol. 2015;11:943–51.

pubmed: 25760975 doi: 10.2217/fon.14.291

Di Costanzo GG, Casadei Gardini A, Marisi G, et al. Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma. Target Oncol. 2017;12:795–803.

pubmed: 28770532 doi: 10.1007/s11523-017-0522-5

Abdel-Rahman O, Lamarca A. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic review and metaanalysis of the impact on survival. Expert Rev Gastroenterol Hepatol. 2017;11:75–83.

pubmed: 27882800 doi: 10.1080/17474124.2017.1264874

Maher VE, Fernandes LL, Weinstock C, et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol. 2019;37: 2730e7.

doi: 10.1200/JCO.19.00318

Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4: 374e8.

Ricciuti B, Genova C, De Giglio A, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol. 2019;145: 479e85.

doi: 10.1007/s00432-018-2805-3

Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018;115: 71e4.

doi: 10.1016/j.lungcan.2017.11.019

Lisberg A, Tucker DA, Goldman JW, et al. Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center. Cancer Immunol Res. 2018;6: 288e94.

doi: 10.1158/2326-6066.CIR-17-0063

Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22: 886e94.

doi: 10.1158/1078-0432.CCR-15-1136

Teulings HE, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33: 773e81.

doi: 10.1200/JCO.2014.57.4756

Cortellini A, Buti S, Agostinelli V, et al. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Semin Oncol. 2019;46: 362e71.

doi: 10.1053/j.seminoncol.2019.10.003

Pinato DJ, Marron TU, Mishra-Kalyani PS, et al. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer. 2021;157:140–52.

pubmed: 34508996 doi: 10.1016/j.ejca.2021.08.020

Tada T, Kumada T, Hiraoka A, et al. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Med. 2022;00:1–12.

Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE—Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90–2.

pubmed: 32891586 doi: 10.1016/j.ad.2019.05.009

Ren Z, Fan J, Xu J, et al. LBA2: Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32). Ann Oncol. 2020;31:S1287.

doi: 10.1016/j.annonc.2020.10.134

Rimini M, Persano M, Tada T, et al. Survival outcomes from atezolizumab plus bevacizumab versus lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. J Cancer Res Clin Oncol. 2023;149(10):7565–77.

pubmed: 36976353 doi: 10.1007/s00432-023-04678-2

Persano M, Rimini M, Tada T, et al. Role of the Prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Oncology. 2023;101(5):283–91.

pubmed: 36657420 doi: 10.1159/000528818

Rimini M, Kang W, Burgio V, et al. Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib. Hepatol Res. 2022;52(12):1050–9.

pubmed: 35960789 doi: 10.1111/hepr.13824

Rapposelli IG, Shimose S, Kumada T, et al. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. ESMO Open. 2021;6(4): 100190.

pubmed: 34144271 pmcid: 8219999 doi: 10.1016/j.esmoop.2021.100190

Kudo M, Finn RS, Qin S, et al. Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT). J Clin Oncol. 2019;37(4):186.

doi: 10.1200/JCO.2019.37.4_suppl.186

Persano M, Rimini M, Tada T, et al. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study. J Cancer Res Clin Oncol. 2023;149(9):5591–602.

pubmed: 36509984 doi: 10.1007/s00432-022-04512-1

Fessas P, Possamai LA, Clark J, et al. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology. 2020;159(2):167–77.

pubmed: 31646612 doi: 10.1111/imm.13141

Johnson DB. Toxicities and outcomes: do steroids matter? Cancer. 2018;124(18):3638–40.

pubmed: 29975416 doi: 10.1002/cncr.31627

Lo JA, Fisher DE, Flaherty KT. Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol. 2015;1:1340–1.

pubmed: 26270186 pmcid: 4679487 doi: 10.1001/jamaoncol.2015.2274

Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681–8.

pubmed: 17982122 pmcid: 2147083 doi: 10.1158/1078-0432.CCR-07-0187

Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193–8.

pubmed: 26282644 pmcid: 5087335 doi: 10.1200/JCO.2015.60.8448

Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4:374–8.

pubmed: 28975219 doi: 10.1001/jamaoncol.2017.2925

Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785–92.

pubmed: 28068177 doi: 10.1200/JCO.2015.66.1389

Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol. 2019;30:187–200.

pubmed: 30642877 pmcid: 6362621 doi: 10.1681/ASN.2018080853

Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol. 2021;13:17588359211031140.

pubmed: 34377156 pmcid: 8327224 doi: 10.1177/17588359211031141

Hatanaka T, Hiraoka A, Tada T, et al. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a landmark analysis. Hepatol Res. 2022;52(5):462–70.

pubmed: 35080087 doi: 10.1111/hepr.13748

Llovet JM, Pinyol R, Kelley RK, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3(4):386–401.

pubmed: 35484418 pmcid: 9060366 doi: 10.1038/s43018-022-00357-2